Drawing for PATHOMICS

USPTO serial 79176495

PATHOMICS

Reviewed by CopyMark Law Group

Reg. 4962140Status 707Renewal
Filing date
Status date
Registration date
May 24, 2016
Examiner
CROWLEY, SEAN MICHAEL
Law office
—

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Need help with PATHOMICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*

Plus Government fees of $1,700

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Mainak H. Mehta

Mainak H. Mehta Procopio, Cory, Hargreaves & Savitch LLP525 B. Street, Suite 2200San Diego, CA 92101UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005[ Pharmaceutical and medical compositions for human and/or veterinary use, namely, for the treatment of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, hormonal and diabetic disorders, coughs, colds, influenza, headaches, stomach and digestive disorders, muscular and/or rheumatic disorders, anti-inflammatory agents, immune system disorders and related diseases, allergic reactions, metabolic disorders, anti-infectives, occular disorders, and for use in oncology; vaccines for human beings and/or animals; adjuvants for use with vaccines; biological laboratory preparations for medical and/or veterinary purposes, namely, for the treatment of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, hormonal and diabetic disorders, coughs, colds, influenza, headaches, stomach and digestive disorders, muscular and/or rheumatic disorders, anti-inflammatory agents, immune system disorders and related diseases, allergic reactions, metabolic disorders, anti-infectives, occular disorders, and for use in oncology; chemical preparations and reagents for medical, pharmaceutical and veterinary purposes, namely, for the treatment of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, hormonal and diabetic disorders, coughs, colds, influenza, headaches, stomach and digestive disorders, muscular and/or rheumatic disorders, anti-inflammatory agents, immune system disorders and related diseases, allergic reactions, metabolic disorders, anti-infectives, occular disorders, and for use in oncology; viruses for the treatment of humans and/or animals; diagnostic preparations for medical purposes; in-vitro diagnostic preparations for medical purposes; in-vivo diagnostic preparations for medical purposes ]SECTION 71 - CANCELLED—
035Investigation and research services relating to cost and business efficiency, all relating to pharmaceuticals, medicine, medicines, vaccines, science, bacteriology, toxicology, chemistry, clinicology, oncology, biochemistry and biotechnology; systemization and compilation of medical information into computer databases; business statistical information all relating to pharmaceuticals, medicine, medicines, vaccines, science, bacteriology, toxicology, chemistry, clinicology, oncology, biochemistry and biotechnology; registration services for diagnostic testing; product demonstration services in the field of diagnostic testing; computer database management services, namely, database management services that allow for information storage in the fields of diagnostic testing and results, database management of medical, hospital, insurance and billing records and information storage and retrieval services in the fields of diagnostic testing and preparations for the treatment, monitoring or diagnosis of disease; trade information services in the fields of medical, health, or clinical care; database management of diagnostic testing and results, database management of medical, hospital, insurance or billing records; collation and provision of business information for the purpose of providing referral services in the fields of medical, health or clinical care; collation and provision of business information in the fields of medicine and pharmacy; collation and provision of business information regarding medical and pharmaceutical testing procedures; collation and provision of business information regarding disease conditions and disease prevention; collation and provision of business information regarding medical, hospital, insurance or billing recordsACTIVE—
042Medical research services; conducting clinical trials for others; medical research laboratory services; medical research laboratory services for the analysis of samples taken from patients; scientific analysis and research services; product development relating to pharmaceuticals, medicines, medicaments and veterinary products; medical and health care research services, namely, clinical testing services, physician testing services for assisting pharmacists, pharmacy testing services, medical laboratory and testing services; medical research into the causes and treatment of influenza and the common coldACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 24, 2025REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Sep 12, 2024RNWLINTERNATIONAL REGISTRATION RENEWED—
Sep 16, 2023INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Aug 8, 2023INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Aug 8, 2023INPCINVALIDATION PROCESSED—
Jul 7, 2023INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Nov 7, 2022NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Nov 7, 202271.PREGISTERED - PARTIAL SEC 71 ACCEPTED—
Oct 31, 2022EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
May 24, 2022PR71POST REGISTRATION ACTION MAILED - SEC.71—
May 23, 2022APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Nov 11, 2021ES71TEAS SECTION 71 RECEIVED—
May 24, 2021REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
May 9, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
Nov 24, 2016ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Sep 16, 2016FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Aug 25, 2016FICSFINAL DISPOSITION NOTICE SENT TO IB—
Aug 25, 2016FIMPFINAL DISPOSITION PROCESSED—
Aug 24, 2016FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
May 24, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 8, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 8, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 4, 2016GPNXNOTIFICATION PROCESSED BY IB—
Feb 17, 2016OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Feb 17, 2016OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Feb 17, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 1, 2016PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jan 26, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 25, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 25, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 25, 2016ALIEASSIGNED TO LIE—
Jan 12, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 31, 2015RFNTREFUSAL PROCESSED BY IB—
Dec 4, 2015RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Dec 4, 2015RFRRREFUSAL PROCESSED BY MPU—
Dec 2, 2015RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 1, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 25, 2015MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 21, 2015DOCKASSIGNED TO EXAMINER—
Nov 21, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 19, 2015REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance